Drift, Shift, Evolve: Keeping Abreast of the Role of Antiviral Therapy in the Management of Seasonal Influenza

 

 

PROGRAM OVERVIEW

The Centers for Disease Control and Prevention (CDC) estimates that 35.5 million people were infected with the influenza virus during the 2018–2019 season, with 16.5 million seeking treatment from a healthcare provider (HCP). Of those infected, 490,600 were hospitalized and 34,200 died from the virus. Vaccination remains a primary yet underutilized prevention method due to numerous barriers and sociodemographic variables. The most frequently and consistently cited barriers for patients not getting vaccinated are lack of cues for action (i.e., direct recommendation from medical personnel), low perceived utility of vaccination, a negative attitude toward influenza vaccines, and fewer previous influenza vaccinations. Given that influenza affects up to 15% of people annually, ensuring that healthcare providers are fully prepared to diagnose and manage the infection with antiviral therapy is essential to optimizing outcomes. This activity was designed to educate HCPs regarding updates on the safety and efficacy of current and emerging antiviral agents and an increased understanding of the place of these agents in clinical practice.

FACULTY

 

William A. Fischer II, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, North Carolina

 

Release date: November 3, 2020
Expiration date: November 3, 2021
Estimated time to complete activity: 1.0 hour

 

TARGET AUDIENCE

This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital and internal medicine settings.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Appraise the role of vaccination in reducing the spread of influenza and improving patient outcomes
  • Employ updated guidelines for the diagnosis of influenza in the hospitalized patient
  • Determine appropriate use of antiviral chemoprophylaxis for individuals at risk of influenza and associated complications
  • Compare current and emerging antiviral agents based on efficacy and safety, dosage and administration, and reduction in duration of illness and complications in order to make individualized treatment decisions for patients with influenza
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity.

During the period of November 3, 2020 through November 3, 2021, participants must:

  • Read the CME/CE information and the learning objectives.
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this free live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this free continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-20-078-H01-P.)

This is a knowledge-based activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This free educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, Ashley Marostica, RN, MSN, and Patima Tanapat, PhD.

FACULTY DISCLOSURES

William A Fischer II, MD

Serves on Adjudication Committees for Janssen Pharmaceutica and Syneos Health.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Continue to Pretest